寻常痤疮致病菌的分离及其药敏结果

对１７３例寻常痤疮患者的痤疮内容物进行了需氧菌和厌氧菌的培养、分离和鉴定，并对所分离的致病菌用试管肉汤稀释法进行了ＭＩＣ的测定。共检出致病菌２１７株，其中痤疮丙酸杆菌７１株（占３２．７２％），颗粒丙酸杆菌３９株（１７．９７％），其余为葡萄球菌（１０７株，占４９．３１％）。药敏试验表明，全部分离株对美满霉素均较敏感（ＭＩＣｓ＜４．０ｍｇ／Ｌ），大部分离株对克林霉素敏感（ＭＩＣ５０＜０．５ｍｇ／Ｌ）；对于甲硝唑和替硝唑，这些致病菌均耐药（ＭＩＣｓ＞３２ｍｇ／Ｌ）。     

针灸综合疗法治疗聚合性痤疮临床研究

目的观察耳穴结合面部刺络闪罐及体针等综合疗法对聚合性痤疮的临床疗效,探讨其作用机理。方法将60例聚合性痤疮患者分为治疗组、对照组各30例。治疗组采用耳穴结合面部刺络闪罐及体针治疗,对照组采用口服米诺环素治疗,共治疗2个疗程。对比观察2组临床疗效及治疗前后血清白细胞介素-1α（IL-1α）水平。结果治疗组临床疗效及总有效率优于对照组,但差异无统计学意义（P〉0．05）。2组治疗后血清IL-1α水平均较治疗前显著下降（P〈0．01）,且治疗组下降水平大于对照组,差异有统计学意义（P〈0．05）。结论针灸综合疗法对聚合性痤疮患者皮损有明显改善,优于米诺环素。针灸调节机体免疫功能可能是其治疗聚合性痤疮的重要机理之一。     

中药内服联合异维A酸红霉素凝胶治疗寻常座疮56例

目的:观察中药内服联合异维A酸红霉素凝胶治疗寻常座疮的临床疗效。方法:100例患者随机分成2组,治疗组56例,予中药内服联合异维A酸红霉素凝胶治疗;对照组44例予中药内服。2组均15天为1个疗程,共治疗2个疗程。结果:治疗组与对照组临床疗效比较,差异有显著性(P<0.05)。结论:中药内服联合异维A酸红霉素凝胶治疗寻常痤疮疗效优于单纯内服中药。     

痤疮净配合中药面膜治疗寻常痤疮临床观察

目的：观察痤疮净配合中药面膜治疗痤疮的临床疗效。方法：86例痤疮患者,辨证分为肺经风热、湿热蕴结、痰湿凝结3型,以痤疮净加减内服配合中药面膜倒模术。结果：肺经风热型疗效最好,湿热蕴结型次之,痰湿凝结型最差,有效率为92％。结论：痤疮净合中药面膜治疗痤疮具有良好的临床疗效。     

E光治疗面部皮肤色素性疾病的临床观察

目的探讨E光治疗面部皮肤常见色素性疾病的临床疗效。方法采用E光治疗仪,使用波长532nm的治疗头治疗面部皮肤常见色素性病变（雀斑、早期脂溢性角化病、黄褐斑、痤疮后色素沉着）242例,4次为1个疗程,每次治疗间隔时间4周,每位患者治疗前后对比拍照、记录参数并进行临床疗效评估。结果 242例患者中各种病变的有效率依次分别为：雀斑95%,早期脂溢性角化病93.55%,痤疮后色素沉着93.65%,黄褐斑17.54%。结论 E光治疗仪治疗面部皮肤常见色素性疾病雀斑、早期脂溢性角化病和痤疮后色素沉着效果好,对黄褐斑疗效不确切。242例患者无1例发生疤痕、色素沉着及色素减退,不良反应少,值得推广应用。     

口服米诺环素联合过氧化苯甲酰治疗痤疮疗效观察

目的 探讨米诺环素联合外用过氧化苯甲酰治疗痤疮的疗效性,分析两者联合用药与单独口服米诺环素在治疗痤疮疗效方面的差异性,从而为痤疮临床治疗提供较好的方案.方法 将45名患者随机分为治疗组和对照组,治疗组接受米诺环素联合过氧化苯甲酰治疗,对照组接受米诺环素治疗,对治疗组和对照组不同疗程(用药后2、4、6、8周及1个月)治愈...     

痤疮模型的研究现状

痤疮由于发病机制复杂,针对不同的发病机制采用的实验模型也不同。目前的实验模型主要包括在体动物模型和体外模型。在体实验动物模型主要包括兔耳模型、金黄地鼠模型、犀鼠模型、墨西哥无毛犬模型。体外模型主要是集中在表皮角质细胞培养和皮脂腺细胞培养。本文旨在对近几年的实验研究方法进行归纳,以利于在实际应用中选择适合的动物模型,为今后筛选防治痤疮的药物研究提供良好的实验平台。     

The potential use of Echinacea in acne: control of Propionibacterium acnes growth and inflammation

Acne is a chronic inflammatory disorder of skin follicles caused by the gram‐positive bacterium Propionibacterium acnes. The possibility was investigated that a standardized preparation of Echinacea purpurea (Echinaforce®), with known antiviral, antiinflammatory and antibacterial properties, might provide a useful alternative treatment in the control of the disease. The herbal extract readily killed a standard laboratory strain of the bacterium and several clinical isolates. In cell culture models of human bronchial epithelial cells and skin fibroblasts, P. acne induced the secretion of substantial amounts of several pro‐inflammatory cytokines, including IL‐6 and IL‐8 (CXCL8), as determined by means of cytokine–antibody arrays. However, the E. purpurea completely reversed this effect and brought the cytokine levels back to normal. Thus Echinaforce® could provide a safe two‐fold benefit to acne individuals by inhibiting proliferation of the organism and reversing the bacterial‐induced inflammation. Copyright © 2010 John Wiley & Sons, Ltd.     

Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Background

The study was conducted to assess the effects of the monophasic combined oral contraceptive containing ethinyl estradiol (EE) 0.03 mg and chlormadinone acetate (CMA) 2 mg (EE/CMA) on papulopustular acne of the face, décolleté (low neck) and back; on moderate comedonal acne of the face; and on seborrhea, alopecia and hirsutism.

Study Design

Three hundred seventy-seven women were randomized (2:1) to receive EE/CMA (n=251) or placebo (n=126) for six medication cycles. Due to the placebo-controlled, double-blind design of the trial, condoms were supplied for contraception. The primary efficacy end point was defined as a reduction of at least 50% in the number of papules and/or pustules of the face from admission to Medication Cycle 6.

Results

In total, 64.1% (161/251) of subjects treated with EE/CMA responded compared with 43.7% (55/126) of those taking placebo (p=.0001). The median reduction in papules/pustules on the face at Cycle 6 compared with admission was 63.6% (EE/CMA) compared with 45.3% (placebo group). For comedonal lesions of the face, the reduction in lesion numbers was 54.8% (EE/CMA) compared with 32.4% (placebo). Moderate papulopustular acne of the décolleté decreased by 92.9% (EE/CMA) vs. 50% (placebo group) and of the back by 86.0% and 58.3%, respectively. For these skin conditions, the p values for the relative difference between groups vs. baseline were <.05 at Cycles 3 and 6, in favor of EE/CMA. As part of a self-assessment rating, at least 70.5% (EE/CMA) vs. 41.3% (placebo) reported an at least satisfactory improvement of their moderate acne. Even 39.8% of women taking EE/CMA reported an “excellent improvement” or “complete resolution” of moderate acne compared with 12.7% taking placebo.

Conclusion

In addition to its contraceptive efficacy described elsewhere, EE/CMA is an effective treatment for moderate papulopustular acne and other androgen-related skin disorders.